COVID-19 care recommendations for people using home-based ventilation

Le français suit

 

As COVID-19 continues to affect our daily lives, it is critical that we try to limit the spread of the virus as much as possible. This is especially applicable for patients who use non-invasive positive-pressure ventilation (NIPPV), mechanical airway clearance devices, or are supported by home ventilation for other chronic respiratory failure syndromes.

Chronic respiratory failure conditions include:

  • Amyotrophic lateral sclerosis (ALS)
  • Chronic obstructive pulmonary disease (COPD)
  • Complicated pneumonia
  • Cystic fibrosis
  • Duchenne muscular dystrophy
  • Myotonic dystrophy
  • Severe obesity hypoventilation syndrome
  • Spinal cord injuries
  • Spinal muscular atrophy
  • Thoracic cage disorders

NIPPV devices can increase the risk of infectious particles being dispersed into the environment, which can then infect the people around you. This risk is especially concerning with poor fitting mask interfaces, high leak, and open ventilation systems with tracheostomy.

To help limit the spread of these particles, the CHEST Foundation has provided recommendations and guidelines to help keep you and your loved ones stay as healthy as possible, which can be downloaded HERE.

***

 

 

 

 

Comme la COVID-19 continue d’affecter notre vie quotidienne, il est essentiel que nous essayions de limiter la propagation du virus autant que possible. Cela s’applique en particulier aux patients qui utilisent la ventilation non invasive (VNI) à pression positive, les dispositifs mécaniques de dégagement des voies respiratoires, ou qui sont soutenus par une ventilation à domicile pour d’autres syndromes d’insuffisance respiratoire chronique.

Les affections liées à l’insuffisance respiratoire chronique comprennent :

  • La sclérose latérale amyotrophique (SLA)
  • Maladie pulmonaire obstructive chronique (MPOC)
  • Pneumonie compliquée
  • Fibrose kystique
  • La dystrophie musculaire de Duchenne
  • La dystrophie myotonique
  • Syndrome d’hypoventilation de l’obésité sévère
  • Lésions de la moelle épinière
  • Atrophie musculaire de la colonne vertébrale
  • Troubles de la cage thoracique

Les VNI à pression positive peuvent augmenter le risque de dispersion de particules infectieuses dans l’environnement, qui peuvent ensuite infecter les personnes autour de vous. Ce risque est particulièrement préoccupant pour les interfaces de masque mal ajustées, les fuites importantes et les systèmes de ventilation ouverts avec trachéotomie.

Pour aider à limiter la propagation de ces particules, CHEST Foundation ont fourni des recommandations et des lignes directrices pour aider vous et vos proches à rester en bonne santé autant que possible, qui vous pouvez télécharger ICI.

 

 

 

virus

Read next...

NMD4C logo with text reading 'Canadian neuromuscular clinical trials network', MDC and IMHA logos at bottom.

NMD4C Launch Canadian Neuromuscular Clinical Trial Network

We are thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work.

Event organizers and participants from SMA outcome measures training, March 2024 in Quebec.

Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network

This past March 23, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered clinicians to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted. 

MDC award $900 000 towards clinical and translational research projects in 2024.

MDC Announce Recipients of 2024 Neuromuscular Clinical and Translational Research Grants

Muscular Dystrophy Canada (MDC) recently announced the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects.

SMA outcome measures training graphic

SMA Outcome Measures Training for Physiotherapists and Occupational Therapists

To support the development and training on validated NMD outcome measures we are pleased to provide opportunities for physiotherapists and occupational therapists to attend training sessions for outcome measures.

Congratulations to the 2024 early career award winners. Dr Mireille Khacho and Dr Jean-Philippe Leduc Gaudet.

Congratulations to the 2024 NMD4C Early Career Awards Recipients

We are excited to announce the recipients of the 2024 NMD4C Early Career Awards! This is the second year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.

Pediatric Rare Disease Clinical Trials and Treatment Network - RareKids-CAN

MICYRN Secures $20 Million Grant from CIHR for a Pediatric Rare Disease Clinical Trials and Treatment Network

The NMD4C are excited to share that MICYRN’s success in securing a $20 million grant from CIHR Institute of Genetics to support the development and execution of RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network.